reliability:

• 21 CFR Part 11: This regulation provides the FDA’s criteria for accepting electronic records and signatures as equivalent to traditional paper records. It stipulates that electronic systems must be validated to ensure they perform reliably and accurately.
• EU Annex 11: This is part of the European Union’s Good Manufacturing Practice guidelines. It specifically addresses the use of computerized systems and the requirements for validation, operation, and security, ensuring that these systems produce records that are trustworthy and reliable.
• GxP Guidelines: This includes various Good Laboratory Practices (GLP), Good Clinical Practices (GCP), and Good Distribution Practices (GDP), underlining the need for CSV within different contexts like product development, clinical trials, and supply chain management.

Documentation

Effective documentation is at the heart of a successful CSV process. Documentation must clearly reflect the system lifecycle, from inception to retirement. The essential documents include:

• Validation Plan: This document outlines the scope, objectives, and the overall strategy for validating a computerised system.
• User Requirements Specification (URS): This identifies the functional requirements that the system must meet to support GxP processes.
• Functional Specification (FS): This elaborates on how the system will operate and addresses the requirements set forth in the URS.
• Validation Protocols and Reports: These documents contain the detailed methodology for validation testing and the results thereof, ensuring that the system meets all requirements.
• Test Scripts: Detailed scripts should be developed for testing specific functionalities of the system to ensure compliance and operational effectiveness.

Review/Approval Flow

The CSV process involves multiple phases, each requiring review and approval to ensure compliance:

1. Planning Phase: Develop the validation plan and user requirements documentation.
2. Requirements Review: Obtain sign-off from stakeholders to confirm that the requirements align with business objectives and regulatory expectations.
3. Design and Development: The system is configured or developed based on approved specifications. This phase should include peer reviews to identify discrepancies or gaps early in the process.
4. Testing Phase: Execute the validation protocols using the test scripts. validate that the system meets requirements and performs intended functions.
5. Review and Approval: Compile a validation report, including all findings, and seek approval from QA and other relevant departments.
6. Deployment and Maintenance: Post-deployment, maintain the system according to a quality management framework. Changes should be managed via a change control process, ensuring ongoing compliance.

Common Deficiencies

Failure to ensure robust validation practices can lead to significant deficiencies in regulatory inspections. Some common issues identified by agencies include:

• Lack of Comprehensive Validation Documentation: Missing or incomplete validation documentation that fails to show a clear understanding of the system’s impact on product quality.
• Insufficient Test Coverage: Failure to test all functionalities or scenarios, especially those critical to compliance and product safety.
• Inadequate Handling of Change Control: Changes made to a system without adequate assessment or documentation of validation impact.
• Failure to Execute Periodic Reviews: Not conducting periodic reviews of validation status can lead to overlooking potential system flaws or compliance risks.

RA-Specific Decision Points

In the course of regulatory affairs, professionals encounter specific decision points that can influence the validation process:

When to File as Variation vs. New Application

Understanding when to file a variation versus a new application is crucial during system changes. Key considerations include:

• Scope of Changes: If the changes impact the method of data collection, processing, or reporting, a new application may be needed. Conversely, if minor adjustments are made that do not significantly affect the regulatory status, a variation may suffice.
• Regulatory Impact: Assess whether the changes will influence the quality or safety of the product. Major impacts typically necessitate a new application.

How to Justify Bridging Data

Bridging data refers to the use of existing data to justify aspects of validation for related systems. Consider the following:

• Regulatory Precedent: Review existing guidance documents or previously accepted bridging strategies by regulatory authorities to support your justification.
• Consistency with Prior Approvals: Ensure that the bridging data aligns with previously validated systems or methods.
• Risk Assessment: Conduct and document a thorough risk assessment to demonstrate that bridging will not compromise data integrity or system reliability.

Conclusion

Computerised System Validation is an essential aspect of regulatory compliance in GxP environments across the US, UK, and EU. By adhering to 21 CFR Part 11, EU Annex 11, and maintaining comprehensive documentation, regulatory affairs professionals can ensure that digital systems support operational integrity, data reliability, and compliance with global standards. Continual assessment of regulatory requirements and evolving technologies will be vital for maintaining effective CSV practices.